Mandos Health to Present New Analyses in Niemann-Pick Disease Type C at the 2025 American Neurological Association Annual Meeting
Mandos Health® by Beren Therapeutics Public Benefit Corporation (P.B.C.) announced today that new analyses detailing the clinical and biological effects of its investigational drug, adrabetadex, in Niemann-Pick Disease Type C (NPC) will be presented at the 150th annual meeting of the American Neurological Association (ANA) September 13–16 in Baltimore, Maryland.
